Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
John Charles Williams
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
City of Hope
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Meditope Biosciences, Inc. is a biotechnology company focused on development of antibody-based cancer products using antibody structural appendages called “meditopes”. Dr. Williams is listed as the Principal Investigator on the funded research grant regarding the use of meditope-enabled antibodies on CAR T cells. Dr. Williams’ investment in Meditope Biosciences, Inc. is related to the funded research because in involves the exclusive licensure to Meditope Biosciences, Inc. of a type of meditope technology. The grant will seek novel improvements in the application of meditope science and thus the SFI is relevant to the proposed research work. Thus, successful completion of the proposed research may have the potential to benefit Meditope Biosciences, Inc., in that it may provide extra validation of the meditope technology which is licensed to them.
In situ Imaging of CAR T-cells
The objective of this application is to exploit our recent discovery and development of a unique, high affinity binding site within a monoclonal antibody (mAb) as a means to add novel functionality to chimeric antigen receptor (CAR) T cell therapies. Specifically, we will generate, characterize, and demonstrate that we can effectively replace an anti-Her2 scFv with an anti-Her2 meditope-enabled Fab or meditope-enabled mAb and to use this site for imaging CAR T cells in vivo. Successful demonstration of this technology will open up new avenues to improve adoptive immunotherapy, a highly promising and emerging treatment applicable to multiple forms of cancer.
Filed on April 27, 2016.
Tell us what you know about John Charles Williams's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
John Charles Williams filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| John Williams | Beckman Research Institute/city of Hope | Conflict of Interest | Meditope Biosciences Inc. | $20,000 - $39,999 |
| John Williams | Beckman Research Institute/city of Hope | Conflict of Interest | Meditope Biosciences Inc. | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.